This week in drug discovery (13-17 January)
News round-up for 13-17 January by DDW Senior Digital Content Editor Diana Spencer.
This week we have seen a number of positive announcements related to the early clinical and preclinical development of immunotherapies, including an islet cell therapy for diabetes, an antibody-drug conjugate and a CAR-T therapy for multiple myeloma, and a peptide-drug conjugate and a vaccine for head and neck cancers.
The top stories:
First evidence of cell transplant without immunosuppression
Positive results have been revealed from the first-in-human study transplanting an islet cell therapy into a patient with type 1 diabetes without the use of immunosuppression.
In vivo BCMA CAR-T candidate shows promise in first human trial
EsoBiotec and Pregene Biopharma have dosed the first patient in an investigator-initiated clinical trial in China of ESO-T01 for relapsed/refractory multiple myeloma.
Heidelberg Pharma progresses multiple myeloma ADC
Heidelberg Pharma is advancing into Cohort 7 in a Phase I/IIa dose escalation study with lead ATAC candidate HDP-101 for the treatment of relapsed or refractory multiple myeloma.
Avacta’s peptide drug conjugate shrinks tumours in salivary gland cancer
Avacta has announced positive early efficacy data for its peptide drug conjugate, AVA6000, demonstrating clinically meaningful tumour shrinkage in patients with salivary gland cancer (SGC).
Vaccine achieves early clinical validation in head and neck cancer
The combination of Scancell’s Modi-1 and a checkpoint blockade has shown promise in HPV negative head and neck squamous cell carcinoma (SCCHN) in an ongoing Phase IIa study.
